These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 14612895)
1. A phase II study of irinotecan plus chronomodulated oxaliplatin, 5-fluorouracil and folinic acid in advanced colorectal cancer patients. Garufi C; Bria E; Vanni B; Zappalà AM; Sperduti I; Terzoli E Br J Cancer; 2003 Nov; 89(10):1870-5. PubMed ID: 14612895 [TBL] [Abstract][Full Text] [Related]
2. Bimonthly chemotherapy with oxaliplatin, irinotecan, infusional 5-fluorouracil/folinic acid in patients with metastatic colorectal cancer pretreated with irinotecan- or oxaliplatin-based chemotherapy. Nobili S; Checcacci D; Filippelli F; Del Buono S; Mazzocchi V; Mazzei T; Mini E J Chemother; 2008 Oct; 20(5):622-31. PubMed ID: 19028627 [TBL] [Abstract][Full Text] [Related]
3. Weekly high-dose 5-fluorouracil as 24-h infusion and folinic acid (AIO) plus irinotecan as second- and third-line treatment in patients with colorectal cancer pre-treated with AIO plus oxaliplatin. Stickel F; Jüngert B; Brueckl V; Schirner I; Brueckl WM; Männlein G; Hegewald J; Mühldorfer S; Bittorf B; Hohenberger W; Hahn EG; Wein A Anticancer Drugs; 2003 Oct; 14(9):745-9. PubMed ID: 14551509 [TBL] [Abstract][Full Text] [Related]
4. Phase I study of the combination of oxaliplatin, irinotecan and continuous infusion 5-fluorouracil in digestive tumors. Abad A; Massutí B; Gallego J; Yuste AL; Manzano JL; Carrato A; Antón A; Marfa X; Diaz-Rubio E; Anticancer Drugs; 2004 Jun; 15(5):469-71. PubMed ID: 15166620 [TBL] [Abstract][Full Text] [Related]
5. Oxaliplatin plus irinotecan and leucovorin-modulated 5-fluorouracil triplet regimen every other week: a dose-finding study in patients with advanced gastrointestinal malignancies. Comella P; Casaretti R; De Rosa V; Avallone A; Izzo F; Fiore F; Lapenta L; Comella G Ann Oncol; 2002 Dec; 13(12):1874-81. PubMed ID: 12453855 [TBL] [Abstract][Full Text] [Related]
6. Oxaliplatin plus raltitrexed and leucovorin-modulated 5-fluorouracil i.v. bolus: a salvage regimen for colorectal cancer patients. Comella P; Casaretti R; Crucitta E; De Vita F; Palmeri S; Avallone A; Orditura M; De Lucia L; Del Prete S; Catalano G; Lorusso V; Comella G Br J Cancer; 2002 Jun; 86(12):1871-5. PubMed ID: 12085178 [TBL] [Abstract][Full Text] [Related]
7. Chronomodulated irinotecan, oxaliplatin, and leucovorin-modulated 5-Fluorouracil as ambulatory salvage therapy in patients with irinotecan- and oxaliplatin-resistant metastatic colorectal cancer. Gholam D; Giacchetti S; Brézault-Bonnet C; Bouchahda M; Hauteville D; Adam R; Ducot B; Ghémard O; Kustlinger F; Jasmin C; Lévi F Oncologist; 2006; 11(10):1072-80. PubMed ID: 17110626 [TBL] [Abstract][Full Text] [Related]
8. Dramatic tumor response of bulky liver metastases following treatment with CPT-11 and a chronomodulated 4-day infusion of 5-fluorouracil, folinic acid and oxaliplatin every 2 weeks in a colorectal cancer patient. Gornet JM; Azoulay D; Lévi F; Yovine A; Misset JL; Goldwasser F Anticancer Drugs; 2000 Apr; 11(4):263-8. PubMed ID: 10898541 [TBL] [Abstract][Full Text] [Related]
9. First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule. Masi G; Allegrini G; Cupini S; Marcucci L; Cerri E; Brunetti I; Fontana E; Ricci S; Andreuccetti M; Falcone A Ann Oncol; 2004 Dec; 15(12):1766-72. PubMed ID: 15550581 [TBL] [Abstract][Full Text] [Related]
10. Irinotecan and chronomodulated infusion of 5-fluorouracil and folinic acid in the treatment of patients with advanced colorectal carcinoma: a phase I study. Garufi C; Dogliotti L; D'Attino RM; Tampellini M; Aschelter AM; Pugliese P; Perrone M; Nisticó C; Comis S; Terzoli E Cancer; 2001 Feb; 91(4):712-20. PubMed ID: 11241238 [TBL] [Abstract][Full Text] [Related]
11. Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial. Lévi FA; Zidani R; Vannetzel JM; Perpoint B; Focan C; Faggiuolo R; Chollet P; Garufi C; Itzhaki M; Dogliotti L J Natl Cancer Inst; 1994 Nov; 86(21):1608-17. PubMed ID: 7932825 [TBL] [Abstract][Full Text] [Related]
12. An alternating regimen of irinotecan/ 5-fluorouracil/folinic acid and oxaliplatin/ 5-fluorouracil/folinic acid in metastatic colorectal cancer: a Phase II trial. Ferrari V; Valcamonico F; Amoroso V; Simoncini E; Vassalli L; Marpicati P; Rangoni G; Grisanti S; Pasinetti N; Marini G Oncology; 2005; 69(4):283-9. PubMed ID: 16282707 [TBL] [Abstract][Full Text] [Related]
13. Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial. Garufi C; Torsello A; Tumolo S; Ettorre GM; Zeuli M; Campanella C; Vennarecci G; Mottolese M; Sperduti I; Cognetti F Br J Cancer; 2010 Nov; 103(10):1542-7. PubMed ID: 20959822 [TBL] [Abstract][Full Text] [Related]
14. Biweekly oxaliplatin plus irinotecan and folinic acid-modulated 5-fluorouracil: a phase II study in pretreated patients with metastatic colorectal cancer. Comella P; Massidda B; Palmeri S; Putzu C; De Rosa V; Izzo F; Fiore F; Casaretti R; Sandomenico C Anticancer Drugs; 2006 Sep; 17(8):985-92. PubMed ID: 16940809 [TBL] [Abstract][Full Text] [Related]
15. Concurrent irinotecan and 5-fluorouracil plus levo-folinic acid given every other week in the first-line management of advanced colorectal carcinoma: a phase I study of the Southern Italy Cooperative Oncology Group. Comella P; Casaretti R; De Vita F; Avallone A; Orditura M; Petrillo A; Gravina A; Faranda A; Comis S; Comella G; Catalano G Ann Oncol; 1999 Aug; 10(8):915-21. PubMed ID: 10509152 [TBL] [Abstract][Full Text] [Related]
16. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). Souglakos J; Androulakis N; Syrigos K; Polyzos A; Ziras N; Athanasiadis A; Kakolyris S; Tsousis S; Kouroussis Ch; Vamvakas L; Kalykaki A; Samonis G; Mavroudis D; Georgoulias V Br J Cancer; 2006 Mar; 94(6):798-805. PubMed ID: 16508637 [TBL] [Abstract][Full Text] [Related]
17. Randomized multicenter phase II study comparing a combination of fluorouracil and folinic acid and alternating irinotecan and oxaliplatin with oxaliplatin and irinotecan in fluorouracil-pretreated metastatic colorectal cancer patients. Bécouarn Y; Gamelin E; Coudert B; Négrier S; Pierga JY; Raoul JL; Provençal J; Rixe O; Krisch C; Germa C; Bekradda M; Mignard D; Mousseau M J Clin Oncol; 2001 Nov; 19(22):4195-201. PubMed ID: 11709562 [TBL] [Abstract][Full Text] [Related]
18. Whole-body hyperthermia (41.8 degrees C) combined with bimonthly oxaliplatin, high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer: a phase II study. Hegewisch-Becker S; Gruber Y; Corovic A; Pichlmeier U; Atanackovic D; Nierhaus A; Hossfeld DK Ann Oncol; 2002 Aug; 13(8):1197-204. PubMed ID: 12181242 [TBL] [Abstract][Full Text] [Related]
19. Irinotecan, oxaliplatin plus bolus 5-fluorouracil and low dose folinic acid every 2 weeks: a feasibility study in metastatic colorectal cancer patients. Martinez J; Martin C; Chacon M; Korbenfeld E; Bella S; Senna S; Richardet E; Coppola F; Bas C; Hidalgo J; Escobar E; Reale M; Smilovich AM; Wasserman E Am J Clin Oncol; 2006 Feb; 29(1):45-51. PubMed ID: 16462502 [TBL] [Abstract][Full Text] [Related]
20. The value of oxaliplatin in combination with continuous infusion +/- bolus 5-fluorouracil and levo-folinic acid in metastatic colorectal cancer progressing after 5FU-based chemotherapy: a GISCAD (Italian Group for the Study of Digestive Tract) cancer phase II trial. Mosconi S; Cascinu S; Zaniboni A; Catalano V; Giordani P; Beretta GD; Martignoni G; Pancera G; Baldelli AM; Poletti P; Curti C; Labianca R Tumori; 2000; 86(6):465-9. PubMed ID: 11218187 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]